1. Cost and effectiveness of the California triple marker prenatal screening program
- Author
-
D Gwynne Tompkinson and George C. Cunningham
- Subjects
Down syndrome ,Pediatrics ,medicine.medical_specialty ,Cost-Benefit Analysis ,Genetic counseling ,Population ,Genetic Counseling ,Prenatal care ,Chorionic Gonadotropin ,Sensitivity and Specificity ,California ,Pregnancy ,Prenatal Diagnosis ,medicine ,Humans ,Genetic Testing ,Neural Tube Defects ,education ,Genetics (clinical) ,education.field_of_study ,medicine.diagnostic_test ,Cost–benefit analysis ,Estriol ,business.industry ,Gestational age ,medicine.disease ,Karyotyping ,Amniocentesis ,Gestation ,Female ,alpha-Fetoproteins ,Down Syndrome ,business ,Biomarkers - Abstract
Purpose: To report the utilization of services offered and pregnancy outcomes for a unique statewide prenatal triple marker screening program and to present a cost-benefit analysis. A state population of 32 million with consider-able ethnic and age distribution and with a wide variety of delivery systems providing prenatal care was considered. The entire pregnant population who appeared for care before 20 weeks gestation, approximately one-half million per year during the years of 1995 to 1997, was included in the study. Methods: Mandatory offering of serum testing, using alpha-fetoprotein from 1986 to 1995, and the addition of human chorionic gonadotropin and unconjugated estriol in 1995, with systematic follow-up of serum screen positives with ultrasound and amniocentesis. This study collected and analyzed the program data and reports of outcomes and collected similar information from the birth defects registry. Results: Triple marker serum screening was accepted by 67.4% of the women eligible and yielded an initial positive rate of 7.3%. More than 90% of the initially screen positive pregnancies were seen at a prenatal diagnostic center. After correction of gestational age, 71.3% had amniocentesis. The overall amniocentesis rate among women screened was 2.6%. The Program's detection rate was predicted to be 85% for neural tube defects, and, based on Monte Carlo modeling, was theoretically calculated to be 62% for Down syndrome. In practice, detection rates were 75% for neural tube defects and 41% for Down syndrome due to lower than expected amniocentesis acceptance rate. Nevertheless, at a 5% discount rate, the screening program was cost beneficial at a ratio of 2.69:1. The cost per case detected was 35,365 and per case prevented was 110,741. Conclusion: It is possible to implement a cost-effective population-based screening in compliance with quality standards in a diverse ethnic population with a variety of health-care providers. Triple marker screening in the second trimester is a cost beneficial program even if utilization of all services is less than ideal.
- Published
- 1999
- Full Text
- View/download PDF